Category: California
|
|
| |
|
California Life Science Firms to Learn "Insider" Strategies for Government Funding at 11th SoCalBio Investor & Partnership Conference
|
 |
Franklin Allen and Glenn Yago, authors of Financing the Future: Market-Based Innovations for Growth, will discuss financial innovations as well as their views on the economic recovery and regulatory reform at a Forum scheduled for August 3 at the Milken Institute.
In Financing the Future, Allen and Yago trace the evolution of financial innovations and how they have advanced a variety of fields. The authors argue that the financial crisis offers a cautionary tale, but shouldn't be used as an opportunity to quash innovation altogether. They identify crucial differences between genuinely useful innovations and instruments designed merely to hide risk and generate quick profits.
There is no charge for the Forum, but preregistration is required. To RSVP, please register online.
CALAsia is a global conference aimed at helping U.S. and Asian life science organizations spotlight growth, technology development and innovation in their respective regions. The two day event in San Diego on October 4-5, 2010 will focus on development strategies in the US and Pacific Rim including regulatory compliance issues facing Asian and American companies, the future of global drug discovery, and financing opportunities.
Application Deadline August 6, 2010
The National Cancer Institute (NCI) recently introduced the Small Business Innovation Research (SBIR) Phase II Bridge Award mechanism, designed to incentivize their phase II awardees to obtain 3rd party financing in order commercialize technologies developed with SBIR funds.
In this session, Directors from the NCI SBIR Development Center will talk to current and potential grantees about the Bridge Award and other opportunities such as their contract topics.
After the presentation, each attendee will have a private meeting with Mr. Michael Weingarten – the Director of the NCI SBIR Development Center – and/or Dr. Ali Andalibi – the Program Director of the NCI SBIR Development Center.
To apply for one-on-one meetings, please send your Executive Summary by August 6, 2010 toevents@sjbiocenter.com. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application.
BIOCOM and BayBio are creating a day and a half conference that will combine the business, research and investment aspects for the industrial biotech community in this unique statewide conference. Through panel discussions, partnering opportunities and ample networking opportunities to extend your relationships. This conference will educate participants on the opportunities and challenges facing industrial biotech companies and ultimately demonstrate why California is a center of innovation in the industrial biotech space.
In business, the decision to support an initiative is frequently made following a live presentation supported by slides. Too often these presentations miss the mark. Cruxio specializes in equipping biomedical companies to develop and deliver clear, powerful strategic stories - usually as live presentations. In the past four years, Cruxio's unique story-development methodology has fueled more than 50 mission-critical presentations, helping to secure more than $500 million in funds or revenue. Join Rob Wishnowsky, founder of Cruxio - the crux of the story - for an interactive overview of five essentials you need to consider to develop your clear, compelling strategic story.
In 2005 Rob Wishnowsky founded Cruxio (the crux of the story), a West Coast company that helps companies develop and deliver clear strategic stories. Cruxio's proprietary processes have been used in more than fifty presentations, securing more than $500 million in funding or revenue. Rob has extensive experience in global strategy, sales and marketing in the fields of life science, diagnostics and biotechnology. 20 years he has led business units, sales forces, strategy formulation, market segmentation, portfolio development and marketing execution, primarily in large corporations (Boehringer Mannheim/Roche Diagnostics, Johnson & Johnson's Lifescan) as well as in early-stage companies. He served on the board of the Biomedical Marketing Association from 2003 to 2007.
Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=206505
Event features a presentation by Ernst & Young on the state of the bioscience industry based on the recent study entitled "Beyond Borders: Global Biotechnology Report 2010"
When: July 23, 2010, 8 am to12:30 pm
Where: Wilshire Grand Hotel in downtown Los Angeles
- Learn how SoCalBio's Group Purchasing Program can slow your company's burn rate and cut down the cost of doing business.
- Meet Group purchasing vendors to learn more about their services and the discounts exclusively offered to SoCalBio member companies.
- Network with your colleagues in device, IVD or biotech companies and learn how they are navigating this down economy.
- Get detailed insight into how SoCalBio can help your organization succeed.
- Get a copy of "Beyond Borders: Global Biotechnology Report 2010," Ernst & Young's 24th annual report on the biotech industry.
What Does Healthcare Reform Mean to
San Diego Businesses?
The recently passed Patient Protection and Affordable Care Act (or healthcare reform law) is attempting to insure more Americans, lower costs and impose new taxes on medical devices. How does the enactment of this far reaching legislation change the way San Diego wireless health and life sciences companies conduct business? San Diego has played an important foundational role in the formation of the wireless healthcare market. How do Don Casey, the CEO of the West Wireless Health Institute,Mike Murphy, the CEO of Sharp Hospitals and Dave Schlotterbeck, the CEO of CareFusion, view this important piece of legislation? What are the opportunities, threats and possibilities for San Diego businesses and how will this industry respond to the new law.
The panel is preceded by a Wireless Health Expo featuring the latest innovations in wireless health products and services. Attendees have an opportunity to experience the latest technologies as well as network with industry representatives from the mHealth sector.
Firms Offer EBC Companies Access to Leading Design Software to Speed Time to Market for Clean Energy and Environmental Technologies
SAN JOSE and SAN RAFAEL, Calif., July 13, 2010 — Autodesk, Inc. (NASDAQ: ADSK) and the Environmental Business Cluster (EBC) have forged an industry partnership to offer benefits of the Autodesk Clean Tech Partner Program to the EBC community so companies can innovate and commercialize their ideas more quickly.
EBC is an award-winning clean tech incubator in Silicon Valley that provides commercialization support and facilities for emerging clean energy and environmental technology companies. The Autodesk Clean Tech Partner Program provides Digital Prototyping software to clean technology companies to enable them to digitally design, visualize and simulate the real-world performance of products before they are built. Creation of digital prototypes can serve as a catalyst to help participants secure financing and effectively market their ideas.
B-Bridge now distributes SCIVAX NanoCulture Plates that enable you to do 3D cell culture using conventional 2D cell culture techniques. The precise nanogrid etched on the bottom of each well promotes cell migration, aggregation, and three-dimensional assembly as spheroids with most cell lines and primary tumor cells. No gels, matrices, or other scaffolds are needed.
The specific spheroid morphology is cell line specific ranging from round dense spheres covered with extracellular matrix to spheroids with glandular structure. The morphology of the spheroids often resembles the morphology of an in vivo tumor with hollow regions and tubules. NanoCulture Plates provide an easy and robust approach to culture virtually any primary tumor.
B-Bridge is also happy to offer Gene Bridges Red/ET Recombineering Technology. Red/ET allows unlimited cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome.
